On Tuesday, Shares of Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA), lost -0.83% to $71.40.
Teva Pharmaceutical Industries, declared that it has successfully filed a Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) for reslizumab. Reslizumab is a humanized anti-interleukin-5 (IL-5) monoclonal antibody (mAb) for the treatment of inadequately controlled asthma in adult patients with elevated blood eosinophils, despite an inhaled corticosteroid (ICS)-based regimen.
“Uncontrolled asthma remains a serious challenge for patients and healthcare professionals despite the availability of standard of care treatment,” said Dr. Michael Hayden, President of Global R&D and Chief Scientific Officer at Teva Pharmaceutical Industries Ltd. “There is a tremendous need for targeted new medicines. Clinical trials have shown that reslizumab significantly reduced the rate of asthma exacerbations and improved lung function in a specific group of patients with elevated eosinophil levels. This group of patients’ asthma was poorly controlled despite being on a standard treatment regimen. The successful filing of the MAA for reslizumab means that this patient population, which often experiences the most severe symptoms, is now one step closer to a new targeted treatment option in Europe.”
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic, specialty, and other pharmaceutical products worldwide. The company operates in two segments, Generic Medicines and Specialty Medicines.
Shares of Huntington Bancshares Incorporated (NASDAQ:HBAN), inclined 0.78% to $11.69, during its last trading session.
Huntington Bancshares Incorporated, declared the release of its mid-cycle, company-run capital stress test results as required by the Dodd-Frank Act. Results can be found on Huntington’s Investor Relations website under the heading “Publications and Filings” (http://huntington-ir.com/main/Regulatory.htm). Results are based on a forward-looking exercise using hypothetical severely adverse macroeconomic assumptions developed by Huntington.
Huntington Bancshares Incorporated operates as a holding company for The Huntington National Bank that provides commercial, small business, consumer, and mortgage banking services. The company’s Retail and Business Banking segment offers financial products and services, counting checking accounts, savings accounts, money market accounts, certificates of deposit, consumer loans, and small business loans; and investments, insurance, interest rate risk protection, foreign exchange hedging, and treasury administration services.
Finally, TCF Financial Corporation (NYSE:TCB), ended its last trade with 0.18% gain, and closed at $16.34.
TCF Financial Corporation, declared quarterly cash dividends on TCF’s common shares, 7.50% Series A Non-Cumulative Perpetual Preferred Stock and 6.45% Series B Non-Cumulative Perpetual Preferred Stock.
A quarterly cash dividend of $0.05 per common share is payable on September 1, 2015 to stockholders of record at the close of business on August 14, 2015. At June 30, 2015, there were 169.1 million common shares outstanding listed on the New York Stock Exchange under the symbol TCB.
A quarterly cash dividend of $0.46875 per depositary share is payable on September 1, 2015 to holders of record of the depositary shares, representing a 1/1,000th interest in a share of the 7.50% Series A Non- Cumulative Perpetual Preferred Stock, at the close of business on August 14, 2015.
TCF Financial Corporation operates as the bank holding company for TCF National Bank that provides various retail and commercial banking products and services. The companys Lending segment offers retail lending services, counting consumer loans for personal, family, and household purposes, such as home purchases, debt consolidation, and financing of home improvements.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
